Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Blood (2012) 119 (26): 6226–6233.
Currently there are no citedby results. Try again later.
